期刊
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
卷 13, 期 3, 页码 463-477出版社
SPRINGER
DOI: 10.1007/s12265-020-10024-5
关键词
Vascular endothelial growth factor inhibitors; Cardio-oncology; Hypertension; Angiogenesis inhibitors; Cardiovascular toxicity; Team-based approach; Multidisciplinary
Angiogenesis inhibitors, also known as vascular endothelial growth factor (VEGF) or vascular signaling pathway (VSP) inhibitors, have improved care of neoplastic diseases over the past decade. However, cardiovascular toxicities associated with these agents, such as hypertension and less commonly left ventricular systolic dysfunction and heart failure, have often been a limiting factor for continued use. Balancing the benefits of these agents with the associated toxicities is critical to ensure these therapies do not negatively impact oncological outcomes. The care of cancer patients with cardiovascular risks is challenging due to the heterogeneity of cardiovascular complications, paucity of evidence-based guidelines, and lack of channels for collaboration among healthcare providers. Herein, we provide a team-based approach for treatment of angiogenesis inhibitor-induced hypertension along with recommendations on monitoring and appropriate selection of anti-hypertensive agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据